ArticleBlood2022

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

Constantine S Tam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.